Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities: Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin

G. Bacci, P. Picci, S. Ferrari, P. Ruggieri, R. Casadei, A. Tienghi, A. B. Del Prever, F. Gherlinzoni, M. Mercuri, C. Monti

Research output: Contribution to journalArticlepeer-review

Abstract

Background. Neoadjuvant chemotherapy is the most accepted treatment for localized osteosarcoma. This has led to a great improvement in limb-sparing surgery and in disease-free survival. Patients with a good response to preoperative chemotherapy showed a higher disease-free survival rate. Current studies examine the possibility of patients whose limbs could be rescued with a poor necrosis and a reduction of the side effects related to aggressive treatments. Methods. Between September 1986 and December 1989, 164 patients entered the second neoadjuvant study conducted at the Rizzoli Institute, Bologna, Italy, for nonmetastatic osteosarcoma of the extremities. Preoperative chemotherapy consisted of two cycles of high-dose methotrexate intravenously (IV) followed by cisplatin intraarterially and doxorubicin IV. After surgery, patients classified as good responders (> 90% tumor necrosis) received three more cycles of these drugs, whereas poor responders (

Original languageEnglish
Pages (from-to)3227-3238
Number of pages12
JournalCancer
Volume72
Issue number11
DOIs
Publication statusPublished - 1993

Keywords

  • limb salvage
  • malignant bone tumors
  • neoadjuvant chemotherapy
  • osteosarcoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities: Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin'. Together they form a unique fingerprint.

Cite this